The Chronic Disease of Addiction Evidence and Lessons from Practice

Size: px
Start display at page:

Download "The Chronic Disease of Addiction Evidence and Lessons from Practice"

Transcription

1 The Chronic Disease of Addiction Evidence and Lessons from Practice Laura G. Kehoe, MD, MPH Medical Director, MGH Substance Use Disorders Unit Bridge Clinic Massachusetts General Hospital Assistant Professor of Medicine, Harvard Medical School

2 Disclosures I have the following relevant financial relationship with a commercial interest to disclose Guest lecture honoraria Reckitt Benckiser

3 Objectives Review of chronic, relapsing model of addiction Comparison with other chronic diseases Lessons from practice Lessons from patients

4

5 Addiction is Irrational Primary, chronic brain disease characterized by compulsive drug seeking and use despite harmful consequences Involves cycles of relapse and remission 40-60% genetic Without treatment addiction is progressive and can result in disability or premature death American Society of Addiction Medicine. April 12, NIDA. August,

6 Addiction is a Developmental Disease

7 Childhood Dreams and Aspirations

8 Acute Care Model As We Know It overdose relapse detox detox relapse overdose Treatment

9 Can You Guess?

10 Circuits Involved in Addiction NIDA

11 Bmax/Kd DA D2 Receptors (Ratio Index) Dopamine D2 Receptors are Lower in Addiction Normal Controls Cocaine Abusers Cocaine Meth Alcohol 3.2` Heroin control addicted Volkow et al., Neuro Learn Mem

12 Withdrawal Normal Euphoria Natural History of Opioid Use Disorder Tolerance & Physical Dependence Acute use Chronic use Slide courtesy of Dan Alford, 2012

13 Addiction is Similar to Heart Disease Decreased Heart Metabolism in Coronary Artery Disease High Decreased Brain Metabolism in Addiction Healthy heart Diseased Heart Low Healthy Brain Diseased Brain

14 Functional Recovery Takes Time Normal 1 month postdetox 14 months Source: Volkow, ND et al., Journal of Neuroscience 21, , 2001

15 Addiction is a Treatable Disorder NIDA. Principles of Drug Addiction Treatment McLellan et al., JAMA, 284: , 2000.

16 Comparable Relapse Rates Slide courtesy of NIDA, Drugs, Brain Behavior: the Science of Addiction

17 Extended Abstinence is Predictive of Sustained Recovery After 5 years if you are sober, you probably will stay that way. It takes a year of abstinence before less than half relapse Dennis et al, Eval Rev, 2007 Slide courtesy of NIDA, Drugs, Brain Behavior: the Science of Addiction

18 Treating a Biobehavioral Disorder Must Go Beyond Just Fixing the Chemistry Pharmacological Treatments (Medications) We Need to Treat the Whole Person! Behavioral Therapies Medical Services Social Services In Social Context Slide courtesy of NIDA, Drugs, Brain Behavior: the Science of Addiction

19 Stacey Stacey is a 43 yof with severe OUD, remote cocaine use disorder, tobacco use disorder, COPD with recurrent pneumonia, marital discord, DCF involvement, trauma. Starts Suboxone with stabilization at 20 mg daily eventually Engaged and in remission x 12 mo, reunited with children, working Needs lung biopsy, makes it through with increase Suboxone and support Rx Tramadol from surgeon - relapse Re-engages stabilizes x 9 months Cravings in setting of custody battle, Rx adjusted Stabilizes with increased support, stress reduction, tx of her anxiety After another year, has pelvic surgery, pain, increased anxiety increase Suboxone and supports did well Note: regarding courts

20 Stephen Stephen is a 40 yom with long hx IVDU heroin, trauma, short stint in the reserves, and now homelessness. My first pt on Suboxone. Immediate engagement, feels normal, gets back to classes, ongoing insomnia 12 step meetings Early refill request UTOX + cocaine, THC Missed appt due to class On nightly news holding up a CVS for OxyContin

21 Stephen Returned to clinic on probation Resumed Rx with shorter visit intervals, support, shorter Rx supplies, engagement in counselling, contingency mgmt, GAD treatment Engagement with VA housing Stabilizes on higher dose Suboxone and increased support Periodic relapses, each shorter Now in remission 2+ years

22 Relapse Requires Increased Support We label patients as not ready or non compliant We ask them to seek a higher level of care on their own, when most ill We refer them for higher level of care yet many of those programs are not evidence based, and are essentially lower level of care What would we do if a cancer survivor had a lymphoma recurrence after years of remission?

23 People Don t Fail Treatment. Treatment Fails People Ed Salsitz, MD Deconstruct the relapse with your patient Good people make bad decisions when SUD active Change takes time, patience and trust When diseases flare, we increase care or enlist the care of other team members. This is no different Trust is an important tool Positive reinforcement (contingency management) Competing priorities Communicate with others No one size fits all just like other diseases Diet controlled pre-diabetes, oral agents, insulin for DM Diet, exercise, statin, beta-blocker, ASA, ACE inhibitors for heart disease

24 Lessons Learned Listen to your patients It s hard to have an addiction Diversion happens Most have used Suboxone in the past and can do home inductions Don t get caught up in the dose- splitting hairs Don t forget about pseudo-addiction Take sleep disturbance seriously advance Suboxone Take report of cravings extremely seriously treat

25 What Next?

26 Our Roles

THE CHRONIC DISEASE OF ADDICTION. J.A. Samander, M.D.

THE CHRONIC DISEASE OF ADDICTION. J.A. Samander, M.D. THE CHRONIC DISEASE OF ADDICTION J.A. Samander, M.D. OBJECTIVES Review of chronic, relapsing model of addiction Comparison with other chronic diseases Lessons from patients Addiction 24.6 million adults

More information

Treating Addiction as a Chronic Disease

Treating Addiction as a Chronic Disease Treating Addiction as a Chronic Disease Sarah E. Wakeman, MD, FASAM Medical Director, MGH Substance Use Disorder Initiative Assistant Professor of Medicine, Harvard Medical School Disclosures Neither I

More information

Addiction Epidemiology, Language and Stigma

Addiction Epidemiology, Language and Stigma Addiction Epidemiology, Language and Stigma Laura G. Kehoe, MD, MPH Medical Director, MGH Substance Use Disorders Unit Bridge Clinic Massachusetts General Hospital Assistant Professor of Medicine, Harvard

More information

Understanding Addiction and Its Impact on the Brain. SDSMA Webinar Matthew Stanley, DO

Understanding Addiction and Its Impact on the Brain. SDSMA Webinar Matthew Stanley, DO Understanding Addiction and Its Impact on the Brain SDSMA Webinar Matthew Stanley, DO Estimated Economic Cost to Society Due to Substance Abuse and Addiction: Illegal drugs: Alcohol: Tobacco: $181 billion/year

More information

Methadone and Naltrexone ER

Methadone and Naltrexone ER Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my

More information

Mass General s Substance Use Disorder Initiative

Mass General s Substance Use Disorder Initiative Mass General s Substance Use Disorder Initiative Martha Kane, PhD Sarah Wakeman, MD, FASAM Clinical and Medical Directors, Mass General Hospital Substance Use Disorder Initiative None Disclosures Objectives

More information

Methadone and Naltrexone ER

Methadone and Naltrexone ER Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Objectives Review Full Opioid

More information

Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users.

Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users. Slide #1 Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale AIDS Program Medical Director South Central Rehabilitation

More information

Opioid Use Disorder Treatment Initiation in Diverse Settings

Opioid Use Disorder Treatment Initiation in Diverse Settings Opioid Use Disorder Treatment Initiation in Diverse Settings Sarah Wakeman, MD, FASAM Medical Director, Mass General Substance Use Disorder Initiative Assistant Professor, Harvard Medical School Disclosures

More information

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. Public Health disclosures Dr. Martin has no conflict of interest to disclose.

More information

MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER

MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. Peter s Health Partners Grand Rounds October 11, 2017 Disclosures One

More information

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives

More information

Pennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story

Pennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story Pennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story Sarah Sharfstein Kawasaki, MD Director of Addictions Services, Pennsylvania Psychiatric

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance

More information

MGH Substance Use Disorder Initiative. Dawn Williamson, RN, DNP, PMHCNS-BC, CARN-AP MGH ED Christopher Shaw, RN, ANP, PMHNP-BC, CARN-AP MGH ACT

MGH Substance Use Disorder Initiative. Dawn Williamson, RN, DNP, PMHCNS-BC, CARN-AP MGH ED Christopher Shaw, RN, ANP, PMHNP-BC, CARN-AP MGH ACT Bridging the Gap: Bridging the Gaps to addiction treatment through comprehensive collaborative practice among Advanced Practice Nurses in a large urban Medical Center Dawn Williamson, RN, DNP, PMHCNS-BC,

More information

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Medication-Assisted Treatment. What Is It and Why Do We Use It? Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite

More information

Alcohol 2: Case Examples

Alcohol 2: Case Examples Alcohol 2: Case Examples Laura G. Kehoe, MD, MPH Medical Director, MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my spouse/partner

More information

Opioid Use Disorder Treatment: Buprenorphine Treatment Basics

Opioid Use Disorder Treatment: Buprenorphine Treatment Basics Opioid Use Disorder Treatment: Buprenorphine Treatment Basics Daniel Warren, MD Eastern Oregon Coordinated Care Organization Provider Forum on Chronic Noncancer Pain Management Pendleton, OR February 24,

More information

Addicted, Alone, Forgotten, and Ashamed

Addicted, Alone, Forgotten, and Ashamed Addicted, Alone, Forgotten, and Ashamed Colleen T. LaBelle, MSN, RN-BC, CARN Nurse Manager, Office-Based Addiction Treatment Director, STATE OBAT, Mass Department Public Health Overdose Deaths per 100,000

More information

Understanding Addiction: Why Can t Those Affected Just Say No?

Understanding Addiction: Why Can t Those Affected Just Say No? Understanding Addiction: Why Can t Those Affected Just Say No? 1 The Stigma of Addiction There continues to be a stigma surrounding addiction even among health care workers. Consider the negative opinions

More information

Addiction Overview. Diane A. Rothon MD. Causes Consequences Treatments. Methadone/Buprenorphine 101 April 1, 2017

Addiction Overview. Diane A. Rothon MD. Causes Consequences Treatments. Methadone/Buprenorphine 101 April 1, 2017 Addiction Overview Causes Consequences Treatments Methadone/Buprenorphine 101 April 1, 2017 Diane A. Rothon MD Why? would you listen to this presentation Review the definition and neurobiology of addiction

More information

Neurobiology of Addiction

Neurobiology of Addiction Neurobiology of Addiction Tiffany Love, Ph.D. Department of Psychiatry The University of Utah What is Addiction? Addiction is a chronic, relapsing, and treatable brain disorder. Compulsive drug seeking

More information

MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St.

MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. Peter s Health Partners, Albany, NY Assistant Professor of Medicine,

More information

The Importance of Psychological Treatment and Behavioral Support

The Importance of Psychological Treatment and Behavioral Support The Importance of Psychological Treatment and Behavioral Support Michael W. Otto, PhD Department of Psychological and Brain Science Boston University Conflicts and Acknowledgements No industry funding

More information

6/27/2017. Disclosures. Overview. Case Overview

6/27/2017. Disclosures. Overview. Case Overview Disclosures Jessica Gray, MD Nothing to disclose Daniel Alford, MD, MPH Nothing to disclose John Renner, MD Overview The intersection of active illicit opioid use, acute pain and severe mental illness

More information

Opioid Use Disorders &Medication Treatment

Opioid Use Disorders &Medication Treatment Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review

More information

STARTING SUBOXONE IN PRIMARY CARE

STARTING SUBOXONE IN PRIMARY CARE Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences STARTING SUBOXONE IN PRIMARY CARE MARK DUNCAN MD UNIVERSITY OF WASHINGTON OBJECTIVES 1. Review evidence of how to

More information

BASIC VOLUME. Elements of Drug Dependence Treatment

BASIC VOLUME. Elements of Drug Dependence Treatment BASIC VOLUME Elements of Drug Dependence Treatment Module 3 Principles of CBT and relapse prevention strategies Introduction to Cognitive Behavioural Therapy Basics of pharmacological treatment Workshop

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

Neurobiological Advances in Addiction Science: Implications For Treatment Nora D. Volkow, M.D. Director

Neurobiological Advances in Addiction Science: Implications For Treatment Nora D. Volkow, M.D. Director Neurobiological Advances in Addiction Science: Implications For Treatment Nora D. Volkow, M.D. Director @NInews Concentration ) Dopamine (nm) Drugs and Natural Rewards ACTIVATE Dopamine in Reward Regions

More information

Medical Assisted Treatment of Opioid

Medical Assisted Treatment of Opioid Medical Assisted Treatment of Opioid Dependence with XR-NTX(Vivitrol) Michael McNamara DO, FACN Medical Director Mental Health Center of Greater Manchester Manchester NH Outline Overview of Opioid Dependence

More information

Opioid Withdrawal, Opioid Substitution, and HIV Infection

Opioid Withdrawal, Opioid Substitution, and HIV Infection Opioid Withdrawal, Opioid Substitution, and HIV Infection R. Douglas Bruce, MD, MA, MS Associate Clinical Professor of Medicine Yale University New Haven, Connecticut Learning Objectives After attending

More information

WHAT CAN I EXPECT?: DUAL SUBSTANCE USE AND MENTAL HEALTH TREATMENT FOR MILITARY POPULATIONS

WHAT CAN I EXPECT?: DUAL SUBSTANCE USE AND MENTAL HEALTH TREATMENT FOR MILITARY POPULATIONS WHAT CAN I EXPECT?: DUAL SUBSTANCE USE AND MENTAL HEALTH TREATMENT FOR MILITARY POPULATIONS René Lento, PhD Lauren Brenner, PhD September 25, 2018 DISCLOSURES None HOME BASE PROGRAM 3 LEARNING OBJECTIVES

More information

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin

More information

The science of the mind: investigating mental health Treating addiction

The science of the mind: investigating mental health Treating addiction The science of the mind: investigating mental health Treating addiction : is a Consultant Addiction Psychiatrist. She works in a drug and alcohol clinic which treats clients from an area of London with

More information

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

ADDICTION OBJECTIVES 4/10/2018 DISCLOSURE

ADDICTION OBJECTIVES 4/10/2018 DISCLOSURE ADDICTION Michael Baron, MD, MPH, FASAM Medical Director Tennessee Medical Foundation - Physician s Health Program DISCLOSURE I have no financial relationships to disclose. I will not discuss off label

More information

John Murphy DO, MS Lynx Healthcare

John Murphy DO, MS Lynx Healthcare Addiction to Pain Medication and Treatment John Murphy DO, MS Lynx Healthcare No Disclosures Objectives 1 Understand basic neurobiology and learning theory around opioid addiction 2 Identify aberrant behavior

More information

Vivitrol Drug Court and Medication Assisted Treatment

Vivitrol Drug Court and Medication Assisted Treatment Vivitrol Drug Court and Medication Assisted Treatment Amy Black, CNP and Judge Fred Moses Court program Self-starters Mission Statement To provide court-managed, medically assisted drug intervention treatment

More information

Management of Opioid Use Disorder in Primary Care

Management of Opioid Use Disorder in Primary Care 1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,

More information

What are Substance Use Disorders?

What are Substance Use Disorders? What are Substance Use Disorders? Sanchit Maruti, MD Michael Goedde, MD University of Vermont Medical Center 1 Disclosures } Drs. Maruti and Goedde receive compensation as consultants to the American Academy

More information

Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco

Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid

More information

III. FREQUENTLY ASKED QUESTIONS

III. FREQUENTLY ASKED QUESTIONS III. FREQUENTLY ASKED QUESTIONS 1. Why do adolescents take drugs? Adolescents experiment with drugs or continue taking them for several reasons, including: To fit in: Many teens use drugs because others

More information

Serious Mental Illness and Opioid Use Disorder

Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorders Arthur Robin Williams, MD MBE Columbia University, Department of Psychiatry Nick Szubiak, MSW, LCSW Director,

More information

OUD & MAR: Caring for Our Communities

OUD & MAR: Caring for Our Communities OUD & MAR: Caring for Our Communities Speaker: Elisabeth Fowlie Mock, MD, MPH Video Resources Diversion Alert/recoveryinme video https://www.youtube.com/watch?v=q1lsmwwwm40 CDC Videos RX Awareness Campaign

More information

Medical Interventions for Addiction in Primary Care Settings. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale University School of Medicine

Medical Interventions for Addiction in Primary Care Settings. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale University School of Medicine Medical Interventions for Addiction in Primary Care Settings R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale University School of Medicine March 23, 2010 NIH Consensus on Drug Treatment Drug Addiction

More information

The Brain, Behavior and Addiction National Family Dialogue January 27, 2010 Presenter: Flo Hilliard, MSH University of Wisconsin-Madison

The Brain, Behavior and Addiction National Family Dialogue January 27, 2010 Presenter: Flo Hilliard, MSH University of Wisconsin-Madison The Brain, Behavior and Addiction National Family Dialogue January 27, 2010 Presenter: Flo Hilliard, MSH University of Wisconsin-Madison Attitudes about addiction and recovery throughout history Disease?

More information

Brain Health and Opioid Abuse

Brain Health and Opioid Abuse 2018 Statewide Tribal Opioid Summit Brain Health and Opioid Abuse Healing From Opiate Addiction Requires Comprehensive Approaches Psychological, Socio-Cultural, and Biological Donald R. Vereen, Jr., M.D.,

More information

Understanding the Brain: What Drugs Can Tell Us

Understanding the Brain: What Drugs Can Tell Us LIVE INTERACTIVE LEARNING @ YOUR DESKTOP Understanding the Brain: What Drugs Can Tell Us Presented by: Dr. Rochelle D. Schwartz-Bloom March 24, 2011 Understanding the Brain: What Drugs Can Tell Us Rochelle

More information

Understanding Addiction. Understanding Addiction. Acknowledgements. KP Regional Pain Symposium August 8, Mary Eno MD, MPH

Understanding Addiction. Understanding Addiction. Acknowledgements. KP Regional Pain Symposium August 8, Mary Eno MD, MPH Understanding Addiction KP Regional Pain Symposium August 8, 2011 Mary Eno MD, MPH Chief of Addiction Medicine SCPMG South Bay Understanding Addiction Why addicted patients baffle and overwhelm us Limbic

More information

Learning Objectives. Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons

Learning Objectives. Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons Marianna Corona Jennifer Foley September 12, 2017 Learning Objectives 2017 Improving Family Outcomes

More information

Infectious Disease and the Opioid Epidemic: Correctional Health

Infectious Disease and the Opioid Epidemic: Correctional Health Infectious Disease and the Opioid Epidemic: Correctional Health Josiah Jody Rich, MD, MPH Professor of Medicine and Epidemiology, Brown University Director of the Center for Prisoner Health and Human Rights,

More information

Neuroscience of Addiction

Neuroscience of Addiction Neuroscience of Addiction Carlton Erickson, Ph.D. Associate Dean for Research and Graduate Studies Distinguished Professor of Pharmacology Director, Addiction Science Research and Education Center College

More information

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are

More information

Opioid Withdrawal, Opioid Substitution, and HIV Infection

Opioid Withdrawal, Opioid Substitution, and HIV Infection Opioid Withdrawal, Opioid Substitution, and HIV Infection R. Douglas Bruce, MD, MA, MS Associate Clinical Professor of Medicine Yale University New Haven, Connecticut Learning Objectives After attending

More information

Addressing Opiate Abuse

Addressing Opiate Abuse Addressing Opiate Abuse William B. Lawson, MD, PhD, DLFAPA Associate Dean of Health Disparities University of Texas at Austin Dell Medical School william.lawson@austin.utexas.edu Opioids Medications that

More information

2/24/2017. Pregnant Women Who Use Drugs: Stigma, Science and Society

2/24/2017. Pregnant Women Who Use Drugs: Stigma, Science and Society Pregnant Women Who Use Drugs: Stigma, Science and Society Mishka Terplan MD MPH FACOG FASAM Professor Departments Obstetrics and Gynecology and Psychiatry Associate Director Addiction Medicine Virginia

More information

DISCLOSURES MANAGEMENT OF OPIOID USE DISORDERS LECTURE COVERS. SUDs ARE IMPORTANT. I have nothing to declare

DISCLOSURES MANAGEMENT OF OPIOID USE DISORDERS LECTURE COVERS. SUDs ARE IMPORTANT. I have nothing to declare MANAGEMENT OF OPIOID USE DISORDERS DISCLOSURES Marc A Schuckit Distinguished Professor of Psychiatry, UCSD Medical School I have nothing to declare SUDs ARE IMPORTANT Affect > 20% of your patients Are

More information

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings BRIAN GARVEY, MD, MPH REBECCA CANTONE, MD OREGON HEALTH & SCIENCE UNIVERSITY SCAPPOOSE RURAL HEALTH CENTER Disclosures

More information

Safina Koreishi, MD, MPH, Medical Director, Columbia Pacific CCO

Safina Koreishi, MD, MPH, Medical Director, Columbia Pacific CCO Using Leadership to Change Practice: A CPCCO s Journey towards Addressing the Opioid Epidemic Oregon Conference on Opioids, Pain and Addiction Treatment, May 19, 2018 Safina Koreishi, MD, MPH, Medical

More information

Medication Assisted Treatment of Substance Use Disorders

Medication Assisted Treatment of Substance Use Disorders 3 rd Annual Challenges & Innovations in Rural Psychiatry Conference Medication Assisted Treatment of Substance Use Disorders June 22, 2016 Medication Assisted Treatment of Substance Use Disorders Richard

More information

FLAME TEEN HANDOUT Week 9 - Addiction

FLAME TEEN HANDOUT Week 9 - Addiction FLAME TEEN HANDOUT Week 9 - Addiction Notes from the large group presentation: What was your overall reaction of the presentation? What did the presenter say about addition? What did you agree with? Was

More information

OPIOID USE DISORDER (OUD) TREATMENT IN A PATIENT CENTERED HEALTH CENTER

OPIOID USE DISORDER (OUD) TREATMENT IN A PATIENT CENTERED HEALTH CENTER OPIOID USE DISORDER (OUD) TREATMENT IN A PATIENT CENTERED HEALTH CENTER Ed Johnson M.Ed., MAC, LPC, CCS Associate Director, Training & Technical Assistance Southeast Addiction Technology Transfer Center

More information

Medication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs

Medication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs

More information

Opioid Use and Justice Involvement: Challenges in Treatment, Engagement, and Continuity

Opioid Use and Justice Involvement: Challenges in Treatment, Engagement, and Continuity Opioid Use and Justice Involvement: Challenges in Treatment, Engagement, and Continuity Holly Hills, Ph.D. June 13, 2017 Department of Mental Health Law and Policy Overview: Persons who have not been in

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

ADAPTING YOUR COURT STRUCTURE

ADAPTING YOUR COURT STRUCTURE ADAPTING YOUR COURT STRUCTURE Developed by: National Drug Court Institute NDCI, March 2018 The following presentation may not be copied in whole or in part without the written permission of the author

More information

4/19/2018. Opioid Use Disorder in Pregnancy OBJECTIVES ANTENATAL TESTING

4/19/2018. Opioid Use Disorder in Pregnancy OBJECTIVES ANTENATAL TESTING Opioid Use Disorder in Pregnancy 2017 Recommendations from ACOG and The Pew Charitable Trust KATHY D. HARTKE, MD, LEGISLATIVE CO-CHAIR AND IMMEDIATE PAST CHAIR, WISCONSIN SECTION OF THE AMERICAN COLLEGE

More information

NALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018

NALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018 NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications

More information

Opioid Task Force Kick-Off Meeting. February 29, 2016

Opioid Task Force Kick-Off Meeting. February 29, 2016 Opioid Task Force Kick-Off Meeting February 29, 2016 Scope of the Opioid Problem and Data Review Olivia Kasirye, MD, MS County Public Health Officer OVERVIEW The Opioid Epidemic Opioid Task Force Development

More information

Harm Reduction and Medical Respite (Dead People Don t Recover) Alice Moughamian, RN,CNS Dave Munson MD

Harm Reduction and Medical Respite (Dead People Don t Recover) Alice Moughamian, RN,CNS Dave Munson MD Harm Reduction and Medical Respite (Dead People Don t Recover) Alice Moughamian, RN,CNS Dave Munson MD Objectives Provide an overview of harm reduction by defining shared language and key terms. Collaboratively

More information

Buprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM. Disclosures

Buprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM. Disclosures Buprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM Disclosures Dr. Bhatnagar: no disclosures to report Dr. Ewing: no disclosures to report 1 Our

More information

Effectively Addressing Co-Occurring Nicotine Dependence and Marijuana Use. Chad Morris, PhD March 7, 2018

Effectively Addressing Co-Occurring Nicotine Dependence and Marijuana Use. Chad Morris, PhD March 7, 2018 Effectively Addressing Co-Occurring Nicotine Dependence and Marijuana Use Chad Morris, PhD March 7, 2018 2018 BHWP Behavioral Causes of Death in U.S. 2018 BHWP 2018 BHWP Health Disparities Population Behavioral

More information

Introduction to the Massachusetts Consultation Service for the Treatment of Addiction and Pain. March 12 and March 13, 2019

Introduction to the Massachusetts Consultation Service for the Treatment of Addiction and Pain. March 12 and March 13, 2019 Introduction to the Massachusetts Consultation Service for the Treatment of Addiction and Pain March 12 and March 13, 2019 Providers Needs Related to Treating Patients with SUD and Chronic Pain Provider

More information

Identification and Treatment of Opioid Use Disorders in Primary Care Settings

Identification and Treatment of Opioid Use Disorders in Primary Care Settings Identification and Treatment of Opioid Use Disorders in Primary Care Settings 17th Annual Primary Care Symposium February 24, 2018 Kelly S. Barth, DO Associate Professor, Psychiatry & Internal Medicine

More information

Opioid Withdrawal, Opioid Substitution Treatment, and HIV Infection

Opioid Withdrawal, Opioid Substitution Treatment, and HIV Infection Opioid Withdrawal, Opioid Substitution Treatment, and HIV Infection R. Douglas Bruce, MD, MA, MS Associate Clinical Professor of Medicine Yale University Chief of Medicine Cornell Scott-Hill Health Center

More information

Patient-Focused Drug Development for Opioid Use Disorder

Patient-Focused Drug Development for Opioid Use Disorder Patient-Focused Drug Development for Opioid Use Disorder Sara Eggers, U.S. Food and Drug Administration Join the conversation at #OUDTreatment #EndTheStigma Patient-Focused Drug Development: Opioid Use

More information

Concurrent Disorders

Concurrent Disorders Concurrent Disorders Dr. Christy Sutherland MD CCFP dipabam Medical Director, PHS Community Services Methadone/Buprenorphine 101 Workshop April 1, 2017 Overview Introduction Epidemiology Treatment Principles

More information

Treating Opioid Addiction

Treating Opioid Addiction Treating Opioid Addiction Some people who start taking opioid pain medications eventually have serious problems with them and become addicted. Every day, 68 people die in the US from opioid overdose. More

More information

Medication Treatment and Opioid Use Disorder

Medication Treatment and Opioid Use Disorder Medication Treatment and Opioid Use Disorder Colleen T. LaBelle, MSN, RN-BC,CARN Program Director, Office-Based Addiction Treatment Director, STATE OBOT-B Boston Medical Center Disclosures I have no disclosures

More information

MAT in the Corrections Setting

MAT in the Corrections Setting MEDICATION ASSISTED TREATMENT AND CORRECTIONS Frank Filippelli, DO, PhD September 2017 MAT in the Corrections Setting Who Does This Affect? What is MAT and What is the Evidence of Efficacy? Emphasis on

More information

Charles P. O Brien, MD, PhD University of Pennsylvania No financial conflicts, patents, speakers bureaus

Charles P. O Brien, MD, PhD University of Pennsylvania No financial conflicts, patents, speakers bureaus Pain & Opioid Epidemic 2018 Charles P. O Brien, MD, PhD University of Pennsylvania No financial conflicts, patents, speakers bureaus Opioids 3400 BC Mesopotamia, Joy plant 1843 morphine by syringe 1874

More information

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE Wasted AN INTRODUCTION TO SUBSTANCE ABUSE Dr. Brian L. Bethel Child and Family Therapist Independent Trainer and Consultant LPCC-S, LCDC III, RPT-S www.brianlbethel.com INTERPLAY COUNSELING & CONSULTING

More information

Recognizing Narcotic Abuse and Addiction and Helping Those With It

Recognizing Narcotic Abuse and Addiction and Helping Those With It Recognizing Narcotic Abuse and Addiction and Helping Those With It Michael McNett, MD Medical Director for Chronic Pain Member, WI Med Society Opioid Subcommittee Ancient History 1995: OxyContin approved

More information

*IN10 BIOPSYCHOSOCIAL ASSESSMENT*

*IN10 BIOPSYCHOSOCIAL ASSESSMENT* BIOPSYCHOSOCIAL ASSESSMENT 224-008B page 1 of 5 / 06-14 Please complete this questionnaire and give it to your counselor on your first visit. This information will help your clinician gain an understanding

More information

Prescription Opioid Addiction

Prescription Opioid Addiction CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett

More information

Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model

Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model Agenda 1 Opioid Addiction in the United States 2 Evidence-based treatments for OUD OUD Treatment: Best Practices 4 Groups: Our Model 2 Groups is a national network of clinics providing affordable, evidencebased

More information

CHANGING CULTURE, BUILDING A SYSTEM, SUPPORTING PATIENTS AND STAFF. Andrew Suchocki, MD, MPH Medical Director Clackamas Health Centers

CHANGING CULTURE, BUILDING A SYSTEM, SUPPORTING PATIENTS AND STAFF. Andrew Suchocki, MD, MPH Medical Director Clackamas Health Centers CHANGING CULTURE, BUILDING A SYSTEM, SUPPORTING PATIENTS AND STAFF Andrew Suchocki, MD, MPH Medical Director Clackamas Health Centers DISCLOSURES None. OVERVIEW Basic description- context and system overview

More information

CFHA 18 th Annual Conference October 13-15, 2016 Charlotte, NC U.S.A. Session # A1

CFHA 18 th Annual Conference October 13-15, 2016 Charlotte, NC U.S.A. Session # A1 Session # A1 Treating Opioid Dependence as a Chronic Condition in Primary Care: Implications for the Training and Practice of Medical and Behavioral Health Providers Daniel Mullin, PsyD, MPH, Director,

More information

Approaches to Treatment of Youth with Opioid Addiction

Approaches to Treatment of Youth with Opioid Addiction Approaches to Treatment of Youth with Opioid Addiction Marc Fishman MD Mountain Manor Treatment Center Johns Hopkins University What should we do with this case? 17 M Onset prescription opioids 15, progressing

More information

Intro to Concurrent Disorders

Intro to Concurrent Disorders CSAM-SCAM Fundamentals Intro to Concurrent Disorders Presentation provided by Jennifer Brasch, MD, FRCPC Psychiatrist, Concurrent Disorders Program, St. Joseph s Healthcare There are all kinds of addicts,

More information

BENZODIAZEPINES: WHAT YOU DON T KNOW CAN HURT YOU

BENZODIAZEPINES: WHAT YOU DON T KNOW CAN HURT YOU BENZODIAZEPINES: WHAT YOU DON T KNOW CAN HURT YOU TABLE OF CONTENTS 4 Benzodiazepine Addiction 8 Xanax Withdrawal Symptoms 11 Professional Help for Benzo Withdrawal is Essential for Success 15 Relapse

More information

Homelessness and Poor Health: Housing as Treatment

Homelessness and Poor Health: Housing as Treatment Homelessness and Poor Health: Housing as Treatment MassHealth PCC Plan / MBHP Webinar Series June 16, 2016 Jessie M. Gaeta, MD BHCHP Link Between Homelessness and Poor Health The medical problems

More information

The Opioid Crisis: What Can Physicians Do About It?

The Opioid Crisis: What Can Physicians Do About It? The Opioid Crisis: What Can Physicians Do About It? Richard S. Schottenfeld, M.D. Professor and Chair, Department of Psychiatry and Behavioral Sciences 2018 Louis J. Kolodner Memorial Lecture Disclosures

More information

Adolescents And Addiction

Adolescents And Addiction Adolescents And Addiction 1) According to the Substance Abuse and Mental Health Services Administration (SAHMSA), over million people over the age of 12 years needed treatment for substance use in 2012.

More information

Johann Hari. Truths 2/29/2016. From the street to the NICU. Treatment works

Johann Hari. Truths 2/29/2016. From the street to the NICU. Treatment works From the street to the NICU Richard Christensen, PA, CAS Johann Hari Treatment works Truths Disconnect with pregnant women seeking treatment Disconnect between community and science Medication is not a

More information

OPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI)

OPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI) OPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI) Case 105- Prep Materials University of Massachusetts Medical School Opioid Conscious Curriculum Learner Prep Objectives The purpose of this prep material

More information

Tobacco Dependence Treatment From Neurobiology through Public Policy

Tobacco Dependence Treatment From Neurobiology through Public Policy Tobacco Dependence Treatment From Neurobiology through Public Policy Mary Ellen Wewers, PhD, MPH, RN Professor Emerita The Ohio State University College of Public Health Disclosures Funding from the National

More information

Neurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP

Neurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP Neurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP Disclosures This speaker has no conflicts of interest to disclose Objectives Define drug abuse and addiction Identify the

More information